Welcome to our dedicated page for Guardion Health Sciences news (Ticker: GHSI), a resource for investors and traders seeking the latest updates and insights on Guardion Health Sciences stock.
Guardion Health Sciences Inc (GHSI) delivers innovative medical foods and nutritional solutions targeting age-related health challenges, with particular focus on ocular health. This news hub provides investors and healthcare professionals with verified updates about the company's scientific advancements, regulatory milestones, and market developments.
Access timely reports on clinical research outcomes, product innovations, and strategic partnerships that demonstrate GHSI's commitment to evidence-based nutritional science. Our curated collection includes earnings announcements, FDA updates, and expert insights from the company's scientific advisory board.
Key updates cover three core areas: clinical research developments in macular health support, regulatory progress for medical food formulations, and strategic initiatives enhancing distribution networks. Bookmark this page to stay informed about GHSI's role in advancing condition-specific nutrition through pharmaceutical-grade research methodologies.
Guardion Health Sciences (GHSI) announced a 1-for-6 reverse stock split effective March 1, 2021, to comply with Nasdaq's minimum bid price rule. The company also completed at-the-market financings, raising a total of $37.2 million, providing it with over $44 million in cash for future growth and acquisitions. The reverse split aims to enhance the attractiveness of GHSI's stock and maintain compliance for continued listing on Nasdaq. The company has approximately 24.4 million shares outstanding post-split, with a focus on ocular health and clinical nutrition.
Guardion Health Sciences (GHSI) announced that its exclusive distributor in Malaysia, Ho Wah Genting Berhad (HWGB), received product registration approval for the immune support dietary supplement Astramern Astra H from the Malaysian National Pharmaceutical Regulatory Agency. This approval, valid for five years, signifies an important step toward commercialization and allows HWGB to package it with another product, Nutra V, enhancing their immune support offerings. Guardion aims to expand its presence in the Asian nutraceutical market through strategic partnerships and product development.
Guardion Health Sciences (GHSI) announced it received a Nasdaq extension until March 15, 2021, to comply with the $1.00 Minimum Bid Price Rule. The company expressed optimism regarding a recent share price increase, believing it may regain compliance soon. Should the share price fail to meet the requirements, a reverse stock split, previously approved by shareholders, will be enacted to maintain Nasdaq listing. The company focuses on ocular health through clinically supported nutrition and medical devices. Compliance with Nasdaq rules remains crucial for GHSI's market presence.
Guardion Health Sciences (Nasdaq: GHSI) announces the appointment of Bret Scholtes as President and CEO, effective January 6, 2021. Scholtes, with nearly a decade in the nutritional products industry, is expected to drive growth and profitability. His previous role at Omega Protein Corporation saw significant revenue and stock price increases. The Board aims to align Scholtes's compensation with shareholder value objectives. The leadership change comes at a challenging time but promises a focus on product development and market expansion.
Guardion Health Sciences (GHSI) is advancing its new vision support drink, Epiq-V, targeting both adult and youth markets. The drink, which contains Lutein, aims to support ocular health and enhance attention for video gaming. Following successful initial testing, final testing is expected to conclude by Q1 2021, with product availability projected 12 to 16 weeks post-testing. Trademark registration for Epiq-V has been secured in China, with U.S. registration pending. The company’s strategy emphasizes innovative product development for domestic and international markets.
Guardion Health Sciences, Inc. (GHSI) reported a significant revenue increase of 57% for the three months ending September 30, 2020, totaling approximately $253,000, up from $161,000 year-over-year. Medical device sales surged by 147% while medical foods grew by 26%. Despite these gains, the net loss decreased to approximately ($2,143,000) or ($0.02) per share. The company is poised for potential Nasdaq delisting due to a share price below $1.00 and is appealing for an extension. Notably, promising clinical data for Lumega-Z® supports product differentiation in the ocular health market.
Guardion Health Sciences announced a new study published on October 26, 2020, in the journal Nutrients. The research compared the efficacy of Lumega-Z®, Guardion's micronized carotenoid liquid supplement, against the AREDS-2 soft gel (PreserVision®). Conducted over six months, results showed Lumega-Z® significantly improved contrast sensitivity (p < 0.001), while AREDS-2 showed no significant change (p > 0.05). The study indicates Lumega-Z® may better meet the needs of those at risk for age-related macular degeneration. Dr. David Evans highlighted the rapid benefits of Lumega-Z® in visual performance.
Guardion Health Sciences, Inc. (NASDAQ: GHSI) is urging stockholders to vote for Proposal 4 at the Annual Stockholders’ Meeting on October 29, 2020. This proposal seeks an extension to effectuate a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, crucial to avoid potential delisting by November 30, 2020. If declined, delisting risks would increase, adversely impacting stock liquidity. The board stresses that every vote is vital for the company's future.
Guardion Health Sciences (GHSI) has announced an investigator-initiated clinical trial for Lumega-Z, its flagship nutritional product, aimed at evaluating its impact on restoring macular pigment and stabilizing vision. Conducted by Dr. Rick Sponsel, the trial will involve glaucoma patients comparing those taking Lumega-Z daily against a control group over 12 months. Dr. Sponsel's expertise in ocular physiology enhances the study's credibility. Guardion aims to differentiate its offerings through measurable clinical outcomes to influence the ocular health market.
Guardion Health Sciences, Inc. (NASDAQ: GHSI) has announced strategic initiatives to enhance shareholder value. The company will focus on differentiation of brands and the integration of an E-commerce platform, alongside expanding clinically supported nutritional products internationally. Guardion has retained Corporate Finance Associates as a financial advisor to explore strategic transactions. The Board has also formed a Strategy Committee to assess business opportunities. Additionally, Guardion is committed to developing direct-to-consumer sales and evidence-based therapies while enhancing its management team.
